The aim of the project is to explore the effect of a drug- polymer complex on Intestinal Inflammatory Bowel Disease (IBD) by demonstrating the link between toll-like receptors (TLR) in the pathogenesi..
The aim of the project is to explore the effect of a drug- polymer complex on Intestinal Inflammatory Bowel Disease (IBD) by demonstrating the link between toll-like receptors (TLR) in the pathogenesis of inflammation and formulate a Silymarin complex as a potential drug formulation. IBD affects approximately 1.6 million Americans, and there are up to 70,000 new cases every year. Proctitis is a condition where the lining of the rectum becomes inflamed; approximately 750,000 Americans live with this condition. Currently, all available pharmaceutical solutions have poor bioavailability, and we anticipate the drug polymer complex with Silymarin will aid in overcoming this issue. We look to develop a stable drug-polymer complex with Silymarin and poly(lactic-co-glycolic) acid (PLGA) polymers using the nano-precipitation methods. PLGA has been chosen as the polymer since it is highly biocompatible and biodegradable. This project investigates and compares complexes formed using PLGA RG502H and PLGA RG504H, a variety of stabilizers, different pH’s and a range of drug to polymer ratios; through comparison of results the optimized combination for producing a stable drug polymer complex will be determined. The concentration was measured utilising Folin-Ciocalteu reagent using UV-visible spectroscopy and the characterization of the drug polymer complex is through Fourier transform Infrared Spectroscopy (FTIR), and time release experiments. Future tests include drug loading and dissociation profile under different pH’s. The future outlook will be to survey for biochemical, and genetic changes in animal tissues to understand the role that TLRs play in the causation of inflammation.